Indeed, the fact that CLA+ memory T cells recirculate between skin and blood was evidenced by action of efalizumab (a monoclonal antibody targeting the CD11a subunit of LFA-1 molecule that blocked lymphocyte extravasation toward the skin) in psoriasis (11) and atopic dermatitis (12) patients, which proved clinical improvement but also resulted in a lymphocytosis effect of CLA+ T cells that caused relapses after treatment discontinuation (13). This evidence concerns the gene ITGAL and atopic eczema.